Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Recent & Breaking News (NDAQ:AXSM)

Mid-Afternoon Market Update: Crude Oil Down 1.5%; Canadian Solar Shares Drop On Earnings Miss

Benzinga.com  March 21, 2017

12 Biggest Mid-Day Losers For Tuesday

Benzinga.com  March 21, 2017

Mid-Day Market Update: Dow Falls 150 Points; Pulmatrix Shares Spike Higher

Benzinga.com  March 21, 2017

Axsome Therapeutics Announces Pricing of Its Public Offering of Common Stock

GlobeNewswire March 21, 2017

Axsome Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire March 20, 2017

Axsome Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

GlobeNewswire March 7, 2017

Axsome Therapeutics to Present at the 29th Annual ROTH Conference

GlobeNewswire February 27, 2017

Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant Depression

GlobeNewswire February 14, 2017

Axsome Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference

GlobeNewswire February 13, 2017

Axsome Therapeutics to Present at the 2017 BIO CEO & Investor Conference

GlobeNewswire February 7, 2017

Axsome Therapeutics to Present at Biotech Showcase 2017

GlobeNewswire January 4, 2017

Axsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation

GlobeNewswire January 3, 2017

Axsome Therapeutics Reports Third Quarter 2016 Financial Results

GlobeNewswire November 14, 2016

Axsome Therapeutics Enters into $20 Million Term Loan Agreement with Silicon Valley Bank

GlobeNewswire November 10, 2016

Axsome Therapeutics Announces Publication of Research Showing AXS-02 Inhibits Pain in Animal Model of Complex Regional Pain Syndrome

GlobeNewswire October 4, 2016

Axsome Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference

GlobeNewswire September 19, 2016

Axsome Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 6, 2016

Axsome Therapeutics Announces Transition of Chief Medical Officer

GlobeNewswire September 2, 2016

Axsome Therapeutics Reports Second Quarter 2016 Financial Results

GlobeNewswire August 9, 2016

Axsome Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference

GlobeNewswire July 5, 2016